Loading provider…
Loading provider…
Gynecologic Oncology Physician in Greenville, SC
NPI: 1457569923Primary Practice Location
PRISMA HEALTH GREENVILLE MEMORIAL HOSPITAL
701 Grove Rd, Greenville, SC
Primary Employer
Prisma Health University Medical Group
prismahealth.org
HQ Phone
Get MD Jeffrey's Phone Numberphone_androidMobile
Get MD Jeffrey's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardKY State Medical License
SC State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 113 | 172 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 55 | 64 |
| 3 | 99204New patient office or other outpatient visit, 45-59 minutes | 48 | 48 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 14 | 15 |
| 5 | 58571Abdominal removal of uterus (250 grams or less) with removal of tubes and/or ovaries using an endoscope | 13 | 13 |
Serial ultrasonographic evaluation of ovarian abnormalities with a morphology index.
Authors: John Hoff, Frederick Ueland, Christopher Desimone
Journal: Gynecol Oncol
Publication Date: 2014-07-25
Differential Expression of KRAS and SIRT1 in Ovarian Cancers with and Without Endometriosis.
Authors: Adam Walter, Bradley Monk, Evanthia Galanis, Sharad Ghamande, Justin Bottsford-Miller, Rodney Rocconi, Thomas Herzog, Robert Coleman, John Nemunaitis, Adnan Munkarah
Publication Date: 2021-03-22
Lead Sponsor: Gradalis, Inc.
Intervention / Treatment: OTHER: Placebo, BIOLOGICAL: Vigil
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology
Intervention / Treatment: BIOLOGICAL: Nivolumab, BIOLOGICAL: Ipilimumab
Lead Sponsor: Gradalis, Inc.
Collaborators: Roche-Genentech
Intervention / Treatment: DRUG: Atezolizumab, BIOLOGICAL: Vigil